Clinical Trials Browser

Phase 1 × Interventional × montanide ISA 51 × Clear all

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 1 Completed

Adenoma, Islet Cell

NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

BreastDermatologicGastrointestinalSarcomaThoracic

Uveal Melanoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Eye Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Skin Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Breast Neoplasms, Male, Muscle Neoplasms, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1 Completed

Melanoma

NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01585350 2016-08-12

MEL58

Phase 1 Completed

Melanoma

NCT00003224 2014-11-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 1 Completed

22 enrolled 14 charts

Melanoma

NCT01012102 2014-02-20

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT00112216 2013-04-24

Immunotherapy of Melanoma Patients

Phase 1 Completed

Melanoma

NCT00845611 2012-04-06

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Phase 1 Completed

Gastrointestinal

Stomach Neoplasms